Clene Inc.
CLNN · XNASCIK 1822791fmd_188PZ53GSBW25XK0G126HYRDRXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 1 | 0 | 1 | 0 | 0 |
| Cost of revenue | – | – | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | (1) | (3) | – | – | – |
| Gross profit | – | – | 0 | 0 | 1 | 0 | 0 |
| Research and development | 10 | 15 | 28 | 32 | 27 | 20 | 14 |
| Total operating expenses | 16 | 20 | 51 | – | – | – | – |
| Operating income | (16) | (20) | (50) | (48) | (41) | (33) | (23) |
| Interest expense | 0 | 1 | 1 | 3 | 5 | 4 | 3 |
| Interest and investment income | – | – | – | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | 0 | 1 | 40 | 18 | (9) | (6) | (3) |
| Income before taxes | (16) | (19) | (10) | (30) | (50) | (39) | (26) |
| Income tax expense | – | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (19) | (10) | (30) | (50) | (39) | (26) |
| Net income | (16) | (19) | (10) | (30) | (50) | (39) | (26) |